Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 5/20 | 0.45 |
| ▸ | NPY4R | P50391 | 5/20 | 0.45 |
| ▸ | NPY1R | P25929 | 4/20 | 0.45 |
| ▸ | NPY2R | P49146 | 2/20 | 0.45 |
| ▸ | APLNR | P35414 | 2/20 | 0.44 |
| ▸ | GLP1R | P43220 | 10/20 | 0.42 |
| ▸ | SCTR | P47872 | 1/20 | 0.42 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.41 |
| ▸ | GCGR | P47871 | 1/20 | 0.40 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16508489 | 0.94 | NPY4R (0.47) | NPY5RNPY4RNPY1RNPY2RAPLNR | |
| SCHEMBL16508567 | 0.91 | NPY4R (0.54) | NPY5RNPY4RNPY1RNPY2RAPLNR | |
| SCHEMBL16508496 | 0.91 | NPY4R (0.45) | NPY5RNPY4RNPY1RNPY2RAPLNR | |
| SCHEMBL16508547 | 0.90 | NPY4R (0.49) | NPY5RNPY4RNPY1RNPY2RAPLNR | |
| SCHEMBL13356182 | 0.89 | GLP1R (0.49) | NPY5RNPY4RNPY1RNPY2RAPLNR | |
| SCHEMBL16508537 | 0.89 | NPY4R (0.49) | NPY5RNPY4RNPY1RNPY2RAPLNR | |
| SCHEMBL16507945 | 0.88 | APLNR (0.50) | NPY5RNPY4RNPY1RNPY2RAPLNR | |
| SCHEMBL16508437 | 0.88 | NPY4R (0.46) | NPY5RNPY4RNPY1RNPY2RAPLNR | |
| SCHEMBL16508501 | 0.88 | NPY4R (0.57) | NPY5RNPY4RNPY1RNPY2RAPLNR | |
| SCHEMBL16508470 | 0.86 | NPY4R (0.54) | NPY5RNPY4RNPY1RNPY2RAPLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110300167-A1 | CXCR5 RECEPTOR COMPOUNDS | ANCHOR THERAPEUTICS, INC. | 2011-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110300167-A1 | CXCR5 RECEPTOR COMPOUNDS | CXCR5, CXCR1, CCR5 | NPY5R 173/4885NPY4R 789/4885NPY1R 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.